Copyright Notice: http://www.ncbi.nlm.nih.gov/books/about/copyright/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Vesco KK, Whitlock EP, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. (Evidence Syntheses, No. 86.)
Bookshelf ID: NBK66094
| Country | HPV | |||||||
|---|---|---|---|---|---|---|---|---|
| Prevalence among women with normal cytology (general population) % (95% CI) | Adjusted Prevalence among women with normal cytology (general population), by region,* % (95% CI)† | Crude age-specific prevalence among women with normal cytology (general population) % (95% CI) (Estimated from Figure 24) | Prevalence of HPV types 16 and 18 among cervical cancer cases % (95% CI) | |||||
| < 25y | 25–34y | 35–44y | 45–54y | 55+y | ||||
| Canada | 9.9 (9.5–10.4) | North America: 11.3 (10.6–12.1) | 26 (22.5–32.5) | 27.5 (22.5–34) | 14 (6.3–25) | 12 (4.4–24) | 12.5 (5.0–25) | 74.3 (67.0–80.6) |
| China | 12.2 (11.8–12.6) | Eastern Asia: 13.6 (12.5–14.9) | 9 (6–14) | 10 (8–12.5) | 13.5 (12–15.5) | 12.5 (10–15) | 10 (7.5–14) | 71.0 (69.8–72.2) |
| England (UK) | 8.9 (8.6–9.1) | Northern Europe: 7.9 (7.4–8.4) | 22 (21.5–23) | 14 (13.5–15) | 7 (6–7.5) | 6 (5–6.5) | 6 (5.0–6.4) | 79.1 (74.4–83.2) |
| Finland | 7.5 (7.1–7.9) | NR | No data available | 18.5 (17–20) | 8.5 (7.5–9) | 4.3 (3.9–5.0) | 4 (3.5–5) | 88.5 (85.2–91.2) |
| France | 12.8 (12.3–13.4) | Western Europe: 8.4 (8.0–8.8) | 43 (35–51) | 31.5 (26.5–38.5) | 19 (16–24) | 21 (16–26.5) | 13 (8–18.5) | 75.6 (73.3–77.8) |
| Germany | 6.3 (5.9–6.8) | Western Europe: 8.4 (8.0–8.8) | No data available | 76.8 (65.1–86.1) | ||||
| India | 7.9 (7.5–8.2) | South-Central Asia: 7.5 (7.0–8.0) | 15.5 (14–18) | 14 (13–15) | 14 (11–15) | 14 (10–16) | 14.5 (9.5–19) | 82.5 (79.5–85.1) |
| Italy | 9.0 (8.7–9.3) | Southern Europe: 6.8 (5.7–7.7) | 22 (19–25) | 10 (9.5–10.5) | 11.5 (8.5–15) | 9.5 (7–13) | 9 (7–12) | 72.1 (67.6–76.4) |
| Netherlands | 3.9 (3.6–4.1) | Western Europe: 8.4 (8.0–8.8) | 16.5 (5–35) | 8 (7.5–9) | 5 (NR) | 3.5 (NR) | 2.5 (NR) | 87.9 (84.6–90.7) |
| Sweden | 5.5 (4.9–6.0) | Northern Europe: 7.9 (7.4–8.4) | 7 (3.5–11) | 7.5 (6–8) | 5 (4.5–6.5) | 5.5 (1–16) | No data available | 68.5 (64.7–72.2) |
| Switzerland | 6.3 (5.9–6.7) | NR | 17.1 (11.5–25.0) | 7.8 (6.4–8.5) | 6.4 (5.7–7.4) | 5.3 (4.7–6.4) | 5.7 (5.0–6.4) | 78.7 (77.0–80.3)‡ |
| United States | 13.3 (13.0–13.6) | North America: 11.3 (10.6–12.1) | 27 (26.5–27.5) | 12 (11–12.5) | 6 (5.5–6.5) | 4.5 (3.5–5) | 3 (2.5–3.5) | 76.6 (74.3–78.8) |
| Country | Cervical Cancer | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crude Incidence Rate (per 100,000 women per year) | Age- standardized Incidence Rate (per 100,000 women per year) | Age-specific incidence rates (per 100,000 women per year) (Estimated from Figure 17) | Crude Mortality Rate (per 100,000 women per year) | Age- standardized Mortality Rate (per 100,000 women per year) | Age-specific mortality rates (per 100,000 women per year) (Estimated from Figure 17) | |||||||
| 15–44y | 45–54y | 55–64y | 65+y | 15–44y | 45–54y | 55–64y | 65+y | |||||
| Canada | 8.5 | 6.6 | 8.5 | 12 | 12 | 11 | 3.2 | 1.9 | 1 | 4 | 5.5 | 10 |
| China | 11.7 | 9.6 | 11 | 21 | 22 | 15 | 5.2 | 4.2 | 2 | 8.5 | 13 | 21.5 |
| England (UK) | 9.3 | 7.2 | 10 | 12 | 10.5 | 13 | 3.6 | 2.0 | 1 | 4.5 | 5 | 10 |
| Finland | 5.2 | 3.7 | 4.5 | 6 | 6 | 9.5 | 1.9 | 0.9 | 0.5 | 1 | 2.5 | 6 |
| France | 9.1 | 7.1 | 9 | 16 | 11.5 | 11 | 3.1 | 1.8 | 1 | 5 | 5 | 7 |
| Germany | 10.6 | 6.9 | 6 | 20 | 15 | 15.5 | 4.8 | 2.3 | 1 | 5.5 | 7 | 12.5 |
| India | 23.5 | 27.0 | 15.5 | 72 | 90 | 68 | 12.8 | 15.2 | 6 | 33 | 53 | 63 |
| Italy | 9.4 | 6.7 | 7.5 | 16.5 | 15 | 11 | 3.0 | 1.5 | 1 | 4 | 4 | 6.5 |
| Netherlands | 7.1 | 5.4 | 7 | 10 | 8 | 11 | 2.8 | 1.5 | 1 | 3 | 3.5 | 9.5 |
| Sweden | 9.7 | 7.4 | 10 | 13 | 13 | 13.5 | 3.8 | 1.8 | 1 | 4 | 5 | 11.5 |
| Switzerland | 5.7 | 4.0 | 5 | 7 | 7 | 10.5 | 1.9 | 0.9 | 0.5 | 1.5 | 2.5 | 6 |
| United States | 7.0 | 5.7 | 7 | 11 | 10 | 10 | 2.4 | 1.7 | 1.5 | 4 | 4.5 | 6 |
Unless otherwise specified, all data from WHO/ICO Information Center on HPV and Cervical Cancer, 2008; http://apps
.who.int/hpvcentre /statistics /dynamic/ico/SummaryReportsSelect.cfm (updated September 15, 2010) - *
Data from de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet. 2007;7:453–459.
- †
Adjusted for region, study type, study design, publication year, sampling collection device, cell storage medium, HPV assay, primer used, study youngest age included, and study oldest age included
- ‡
Western Europe regional estimated used instead as specific data unavailable
Data from de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet. 2007;7:453–459.
Adjusted for region, study type, study design, publication year, sampling collection device, cell storage medium, HPV assay, primer used, study youngest age included, and study oldest age included
Western Europe regional estimated used instead as specific data unavailable
Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Show details- PDF version of this title (2.5M)
-
Cervical Cancer and HPV: Prevalence, Incidence and Mortality Rates - Screening f...
Cervical Cancer and HPV: Prevalence, Incidence and Mortality Rates - Screening for Cervical CancerBookshelf
-
References - Screening for Breast Cancer
References - Screening for Breast CancerBookshelf
-
Acknowledgements - Screening for Breast Cancer
Acknowledgements - Screening for Breast CancerBookshelf
-
Discussion - Screening for Breast Cancer
Discussion - Screening for Breast CancerBookshelf
Your browsing activity is empty.
Activity recording is turned off.
See more...